G&S Capital’s CRISPR Therapeutics CRSP Stock Holding History

G&S Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-250	Closed	-$10K	–	86
2020 Q1	$10K	Hold	250	–	–	0.02%	133
2019 Q4	$15K	Hold	250	–	–	0.01%	169
2019 Q3	$10K	Hold	250	–	–	0.01%	166
2019 Q2	$12K	Hold	250	–	–	0.01%	170
2019 Q1	$9K	Hold	250	–	–	0.01%	175
2018 Q4	$7K	Buy	250 +150	+150%	+$5.21K	0.01%	165
2018 Q3	$4K	Buy	+100	New	+$5.24K	﹤0.01%	190

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

G&S Capital's CRSP Position: Q2 2020 in Review

G&S Capital sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 250 shares — an estimated $10K sold.

G&S Capital first reported a position in CRSP in Q3 2018 and held it in 7 quarters. The position peaked at $15K in Q4 2019. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

G&S Capital reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
G&S Capital sold 250 CRISPR Therapeutics shares in Q2 2020, an estimated $10K.
G&S Capital first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 7 quarters.
G&S Capital's CRISPR Therapeutics position peaked at $15K in Q4 2019.
276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on G&S Capital's 13F filing for Q2 2020, filed 24 Jul 2020.